Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) following atezolizumab and bevacizumab treatment for hepatocellular carcinoma.
СтатьяКлинический случайСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Yi-Xiao, Wang Rui-Yun, Hao Yan-Lei
Аннотация
OBJECTIVE: To present a case of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) following atezolizumab and bevacizumab therapy and systematically review the literature on immune checkpoint inhibitor (ICI)-associated antibody-mediated central nervous system (CNS) inflammatory demyelinating diseases.
BACKGROUND: While ICIs have transformed cancer treatment, they can trigger diverse neurological immune-related adverse events. Autoimmune demyelinating disorders remain uncommon, with sparse published cases linking ICIs to MOGAD. We report a novel case of MOGAD developing after administration of atezolizumab plus bevacizumab.
METHOD: We conducted a retrospective chart review of the index case and performed a systematic literature review (January 1, 2001, to April 30, 2025) of reported antibody-mediated CNS demyelinating disorders associated with ICIs.
RESULT: This represents the first documented MOGAD case during atezolizumab and bevacizumab treatment for hepatocellular carcinoma. The patient achieved a favorable response to intravenous methylprednisolone and immunoglobulin therapy. Further research is warranted to elucidate the pathogenesis underlying ICI-associated MOGAD.
BACKGROUND: While ICIs have transformed cancer treatment, they can trigger diverse neurological immune-related adverse events. Autoimmune demyelinating disorders remain uncommon, with sparse published cases linking ICIs to MOGAD. We report a novel case of MOGAD developing after administration of atezolizumab plus bevacizumab.
METHOD: We conducted a retrospective chart review of the index case and performed a systematic literature review (January 1, 2001, to April 30, 2025) of reported antibody-mediated CNS demyelinating disorders associated with ICIs.
RESULT: This represents the first documented MOGAD case during atezolizumab and bevacizumab treatment for hepatocellular carcinoma. The patient achieved a favorable response to intravenous methylprednisolone and immunoglobulin therapy. Further research is warranted to elucidate the pathogenesis underlying ICI-associated MOGAD.